文献速递胃肠动力与功能性疾病

大麻二酚治疗特发性和糖尿病性胃轻瘫疗效与安全性的随机对照试验

A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-07-22

这项随机双盲安慰剂对照试验纳入44例特发性或糖尿病性胃轻瘫患者,比较4周大麻二酚(CBD)每日两次(递增至20 mg/kg/d)与安慰剂的效果。CBD组胃轻瘫主要症状指数总分、无法完成正常餐量、每24小时呕吐次数和总体症状严重度均较安慰剂改善,液体营养耐受量提高但胃排空减慢。

要点

  • CBD每日两次递增至20 mg/kg/d治疗4周可改善胃轻瘫症状。
  • CBD提高液体营养饮用的舒适 fullness 量和最大耐受量但减慢胃排空。
  • 最常见不良事件为腹泻14例、乏力8例、头痛8例和恶心7例。

核心结论

  • CBD可缓解胃轻瘫患者的症状并改善液体营养摄入的耐受性,尽管胃排空减慢。

研究设计与样本

  • 随机双盲安慰剂对照研究,纳入44例非手术性胃轻瘫且固体胃排空延迟的患者,其中特发性32例、1型糖尿病6例、2型糖尿病6例。
  • CBD组接受Epidiolex每日两次递增至20 mg/kg/d治疗4周,安慰剂对照组接受安慰剂。
  • 5例患者未能耐受全剂量递增;3例在完成4周治疗前退出(安慰剂组2例,CBD组1例);95%完成4周治疗和日记记录。
  • 治疗4周后测量胃排空、胃容积和Ensure饱感试验(1 kcal/mL,30 mL/min),评估舒适饱腹量和最大耐受量。
  • 患者接受FAAH和CNR1基因分型。

主要发现

  • 与安慰剂相比,CBD降低胃轻瘫主要症状指数总分(P = .008)。
  • 与安慰剂相比,CBD降低无法完成正常餐量的症状(P = .029)。
  • 与安慰剂相比,CBD降低每24小时呕吐发作次数(P = .006)。
  • 与安慰剂相比,CBD降低总体症状严重度(P = .034)。
  • CBD组患者舒适饱腹量和最大耐受量更高,胃排空更慢。

关键数值与推荐

  • 最常见不良事件:腹泻14例、乏力8例、头痛8例、恶心7例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 5例患者未能耐受全剂量递增。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Cannabis (delta-9-tetrahydrocannabinol), a nonselective cannabinoid-receptor agonist, relieves nausea and pain. Cannabidiol (CBD), a cannabinoid receptor 2 inverse agonist with central effects, also reduces gut sensation and inflammation. We compared the effects of 4 weeks of treatment with pharmaceutical CBD vs placebo in patients with idiopathic or diabetic (diabetes mellitus) gastroparesis. METHODS: We performed a randomized, double-blinded, placebo-controlled study of CBD twice daily (Epidiolex escalated to 20 mg/kg/d; Jazz Pharmaceuticals, Dublin, Ireland) in patients with nonsurgical gastroparesis with delayed gastric emptying of solids (GES). Symptoms were assessed by the Gastroparesis Cardinal Symptom Index Daily Diary. After 4 weeks of treatment, we measured GES, gastric volumes, and Ensure (Abbott Laboratories, Abbott Park, IL) satiation test (1 kcal/mL, 30 mL/min) to assess volume to comfortable fullness and maximum tolerance. Patients underwent specific FAAH and CNR1 genotyping. Statistical analysis compared 2 treatments using analysis of variance including baseline measurements and body mass index as covariates. RESULTS: Among 44 patients (32 idiopathic, 6 diabetes mellitus type 1, and 6 diabetes mellitus type 2), 5 patients did not tolerate full-dose escalation; 3 withdrew before completing 4 weeks of treatment (2 placebo, 1 CBD); 95% completed 4 weeks of treatment and diaries. Compared with placebo, CBD reduced the total Gastroparesis Cardinal Symptom Index score (P = .008), inability to finish a normal-sized meal (P = .029), number of vomiting episodes/24 hours (P = .006), and overall symptom severity (P = .034). Patients treated with CBD had a higher volume to comfortable fullness and maximum tolerance and slower GES. FAAH rs34420 genotype significantly impacted nutrient drink ingestion. The most common adverse events reported were diarrhea (14 patients), fatigue (8 patients), headache (8 patients), and nausea (7 patients). CONCLUSIONS: CBD provides symptom relief in patients with gastroparesis and improves the tolerance of liquid nutrient intake, despite slowing of GES. CLINICALTRIALS: gov NCT #03941288.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Zheng T, BouSaba J, Taylor A, et al. A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis. Clin Gastroenterol Hepatol. 2023. PMID: 37482172. doi:10.1016/j.cgh.2023.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。